Lucas Meredith
Nurse Practitioner · Richland, WANPI 1841902053
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,409 of the $12,289 with a category attached, or 60.3%. 31 manufacturers reported payments, led by Biocryst Pharmaceuticals, Inc. at 38.1% of the total. 2025 is the largest year on record at $8,015, 8.9 times the $896 reported in 2023. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $45.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$5K
- AstraZeneca$2K
- Sanofi$812
- Regeneron Healthcare Solutions, Inc.$637
- Genentech USA, Inc.$472
- Blueprint Medicines Corporation$432
- plus $3K from 25 others
What the payments were for
- Consulting fees$2,71422%
- Speaking & faculty fees$4003%
- Travel & lodging$1,66614%
- Food & beverage$7,40960%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 13 | $4,687 |
| AstraZeneca | 60 | $1,799 |
| Sanofi | 32 | $812 |
| Regeneron Healthcare Solutions, Inc. | 28 | $637 |
| Genentech USA, Inc. | 11 | $472 |
| Blueprint Medicines Corporation | 9 | $432 |
| GSK | 26 | $403 |
| Cycle Pharmaceuticals Inc | 1 | $400 |
| Novartis | 15 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $247 |
| Pharming Healthcare, Inc. | 12 | $226 |
| Incyte Corporation | 2 | $219 |
| Ionis Pharmaceuticals, Inc. | 3 | $196 |
| Lilly USA, LLC | 6 | $167 |
| LEO Pharma Inc. | 3 | $153 |
| CSL Behring | 7 | $153 |
| ADMA Biomanufacturing LLC | 1 | $150 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Verona Pharma, Inc. | 4 | $97 |
| Greer Laboratories, Inc. | 1 | $96 |
| Pfizer | 4 | $88 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $67 |
| Biocryst US Sales Co., LLC | 2 | $63 |
| Amgen | 3 | $54 |
| Viatris Specialty LLC | 2 | $52 |
| Alk-abello, Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,289 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $48,017 |
| Advair HfaFluticasone Propion/Salmeterol | 69 | $44,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $43,706 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $14,690 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,844 |
| DuleraMometasone/Formoterol | 24 | $10,351 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $10,175 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,861 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,341 |
| Pulmicort FlexhalerBudesonide | 17 | $5,202 |
| Azelastine Hcl | 121 | $4,635 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $4,559 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $4,018 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $3,857 |
| Ipratropium Bromide | 123 | $3,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $403 | $58,39676 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Pulmicort Flexhaler | $1,799 | $20,40458 claims |
| Boehringer IngelheimSpiriva Respimat | $31 | $13,84418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Richland
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
- Jessica ArmitageSumner$46K
- Lia Duque Estrada de BarrosSeattle$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.